{
  "stages": {
    "I": {
      "primary_treatments": ["Surgical Resection (Lobectomy)"],
      "surgery": ["Lobectomy"],
      "adjuvant": [],
      "alternatives": ["SBRT (Stereotactic Body Radiotherapy)", "Clinical Trial"],
      "follow_up": ["CT chest q6m for 2y then yearly"]
    },
    "II": {
      "primary_treatments": ["Surgery + Adjuvant Platinum-based Chemotherapy"],
      "surgery": ["Lobectomy or pneumonectomy"],
      "adjuvant": ["Platinum chemo"],
      "alternatives": ["Chemoradiation", "Clinical Trial Participation"],
      "follow_up": ["CT chest q6m for 2y"]
    },
    "III": {
      "primary_treatments": ["Concurrent Chemoradiation followed by Immunotherapy"],
      "systemic": ["Concurrent chemo + radiation"],
      "immunotherapy": ["Durvalumab consolidation if PD-L1+"],
      "alternatives": ["Sequential Chemotherapy and Radiation", "Clinical Trial"],
      "follow_up": ["CT q3-6m"]
    },
    "IV": {
      "primary_treatments": ["Targeted Therapy or Immunotherapy (based on markers)"],
      "targeted": {
        "EGFR": "Osimertinib",
        "ALK": "Alectinib",
        "ROS1": "Crizotinib"
      },
      "immunotherapy": ["Pembrolizumab if PD-L1 â‰¥50%"],
      "alternatives": ["Platinum-based Doublet Chemotherapy", "Clinical Trial"],
      "follow_up": ["Imaging q6-12w"]
    }
  }
}
